Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan or vincristine
Background Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C[TM]), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models gr...
Saved in:
Published in | BMC cancer Vol. 11; p. 124 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
BioMed Central Ltd
08.04.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C[TM]), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously. Methods Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx.sup.[R].sup.; 15 mg/kg) and irinotecan (Irinophore C[TM]; 25 mg/kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-measured changes in vascular permeability/flow (K.sub.trans ). Changes in CD31 staining density, basement membrane integrity, pericyte coverage, blood vessel diameter were also assessed. Results The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p [less than] 0.05-0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3 fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p [less than] 0.001). In contrast there was a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p [less than] 0.01), with the greatest effect observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant reduction in K.sub.trans in the orthotopic tumors (p [less than] 0.05). Conclusion The results are consistent with a partial restoration of the blood-brain barrier following treatment. Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more mature and a vascular network that was more evenly distributed. Taken together the results suggest that treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor vasculature. |
---|---|
AbstractList | Background Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C[TM]), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously. Methods Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx.sup.[R].sup.; 15 mg/kg) and irinotecan (Irinophore C[TM]; 25 mg/kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-measured changes in vascular permeability/flow (K.sub.trans ). Changes in CD31 staining density, basement membrane integrity, pericyte coverage, blood vessel diameter were also assessed. Results The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p [less than] 0.05-0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3 fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p [less than] 0.001). In contrast there was a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p [less than] 0.01), with the greatest effect observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant reduction in K.sub.trans in the orthotopic tumors (p [less than] 0.05). Conclusion The results are consistent with a partial restoration of the blood-brain barrier following treatment. Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more mature and a vascular network that was more evenly distributed. Taken together the results suggest that treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor vasculature. Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C[TM]), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously. Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx.sup.[R].sup.; 15 mg/kg) and irinotecan (Irinophore C[TM]; 25 mg/kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-measured changes in vascular permeability/flow (K.sub.trans ). Changes in CD31 staining density, basement membrane integrity, pericyte coverage, blood vessel diameter were also assessed. The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p [less than] 0.05-0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3 fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p [less than] 0.001). In contrast there was a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p [less than] 0.01), with the greatest effect observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant reduction in K.sub.trans in the orthotopic tumors (p [less than] 0.05). The results are consistent with a partial restoration of the blood-brain barrier following treatment. Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more mature and a vascular network that was more evenly distributed. Taken together the results suggest that treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor vasculature. |
Audience | Academic |
Author | Yapp, Donald T Strutt, Dita Masin, Dana Yung, Andrew Anantha, Malathi Bally, Marcel B Kozlowski, Piotr Verreault, Maite Waterhouse, Dawn |
Author_xml | – sequence: 1 fullname: Verreault, Maite – sequence: 2 fullname: Strutt, Dita – sequence: 3 fullname: Masin, Dana – sequence: 4 fullname: Anantha, Malathi – sequence: 5 fullname: Yung, Andrew – sequence: 6 fullname: Kozlowski, Piotr – sequence: 7 fullname: Waterhouse, Dawn – sequence: 8 fullname: Bally, Marcel B – sequence: 9 fullname: Yapp, Donald T |
BookMark | eNptUU1LxDAQDbKCrnr3GPBcTdo0bY8ifoHgRbwu03TSHUmTJckq-Fv8sXZRZA8yh3k83rzHY5Zs4YNHxs6luJSy1VdSNbIolWgKKQtZqgN2_Ect9vARW6b0JoRsWtEes69XSGbrIHIf4gSOPiFT8Jw8DzGvQw4bMnx0FHoHKYcJuA3OhQ_y4yzKEd7Rh23iOSLkCX3mH5TX3NGGhqKHhAP34MMGYqZdUMbZIE47NOckHiynSD5kNLDL5O_kTaSUyeMpO7TgEp797hP2cnf7cvNQPD3fP95cPxWjbrpCA5hOY429VbWFWg-m12WrETpTm0YLK8BU1QCiKWGwWqHoxFAZhSU2Ck11wi5-bEdwuCJvw1zLTJTM6rqslaqUaLtZdfmPap4BJzLzMyzN_N7BN2w2goQ |
ContentType | Journal Article |
Copyright | COPYRIGHT 2011 BioMed Central Ltd. |
Copyright_xml | – notice: COPYRIGHT 2011 BioMed Central Ltd. |
DOI | 10.1186/1471-2407-11-124 |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2407 |
ExternalDocumentID | A254434089 |
GroupedDBID | --- -A0 23N 2VQ 2WC 3V. 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ABVAZ ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ AEAQA AENEX AFGXO AFKRA AFNRJ AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C1A C24 C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR IPNFZ ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB |
ID | FETCH-LOGICAL-g679-6aac96e5ebf45fa56dcb6286ea9c5c760f0ac33da072adf64e090d3c4e2e74ec3 |
IEDL.DBID | M48 |
ISSN | 1471-2407 |
IngestDate | Fri Feb 23 00:16:26 EST 2024 Fri Feb 02 04:28:29 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-g679-6aac96e5ebf45fa56dcb6286ea9c5c760f0ac33da072adf64e090d3c4e2e74ec3 |
ParticipantIDs | gale_infotracmisc_A254434089 gale_infotracacademiconefile_A254434089 |
PublicationCentury | 2000 |
PublicationDate | 20110408 |
PublicationDateYYYYMMDD | 2011-04-08 |
PublicationDate_xml | – month: 04 year: 2011 text: 20110408 day: 08 |
PublicationDecade | 2010 |
PublicationTitle | BMC cancer |
PublicationYear | 2011 |
Publisher | BioMed Central Ltd |
Publisher_xml | – name: BioMed Central Ltd |
SSID | ssj0017808 |
Score | 1.9845791 |
Snippet | Background Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with... Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal... |
SourceID | gale |
SourceType | Aggregation Database |
StartPage | 124 |
SubjectTerms | Blood-vessels Care and treatment Dosage and administration Doxorubicin Glioblastoma multiforme Patient outcomes Tumors Vincristine |
Title | Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan or vincristine |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEA66gngRn7i6LjkInqrZbZq2B5FVFBHWg6iIF8lTCmu6duvrv_hjnanxBeKll0xamklmvsm8CNkCFS55ZnTUzyWPQOOzSCmDYWKJ7bHcJZZhNvLwTJxc8tPr5Po7PTos4ORP0w77SV1Wo52Xh9d9OPB7zYHPxG4PBCx6CVLMEQN9NU1m-liWCwP5-LdPIc2a_nRf1J9Oyz_eEOTzD01zvEDmA0Skgw-eLpIp65fI7DA4wZfJ21WIHqUeAecoZFLSwlN0wpR1OS40vRsVpQJoXJf3kjrgdvkMWgqIamw4hIVZ6VeQOcXbWDoqxoWJUK0Z6qUHa7pqKnMAGqUIbUOjrwktHS2qwmOBB4nfpE-F142w8HaFXBwfXRyeRKHJQnQn0jwSUupc2MQqxxMnE2G0wmxVK3Od6FQwx6SOYyNZ2pfGCW5Zzkysue3blFsdr5KWL71dI1Sl2mROMW6d4bkE5OlUjxmdNUanFW2yjYt6i7yEX9UyJADAbKxBdTvAamkxZ1neJp1flLDj9Y_h9f-HN8jcx8Uvj1jWIa26erSbgBxq1W0s7m6zLeB5fnDzDkUdx94 |
link.rule.ids | 315,783,787,867,24332,27938,27939 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vascular+normalization+in+orthotopic+glioblastoma+following+intravenous+treatment+with+lipid-based+nanoparticulate+formulations+of+irinotecan+or+vincristine&rft.jtitle=BMC+cancer&rft.au=Verreault%2C+Maite&rft.au=Strutt%2C+Dita&rft.au=Masin%2C+Dana&rft.au=Anantha%2C+Malathi&rft.date=2011-04-08&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=11&rft.spage=124&rft_id=info:doi/10.1186%2F1471-2407-11-124&rft.externalDocID=A254434089 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |